Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
BPC-157 and TB-500 BPC-157 is frequently paired with TB-500 (a thymosin beta-4 fragment) for recovery
All products are intended for scientific research and not for human or animal consumption
For a side-by-side comparison of the two individual compounds, see: BPC-157 vs TB-500
Aunque continuamente se realizan nuevos estudios, aqu estn algunos de los resultados ms significativos de los ensayos clnicos hasta la fecha
Write a review Rating Bad Good News ATTENTION
Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
